losartan has been researched along with Ureteral Obstruction in 37 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Ureteral Obstruction: Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks." | 8.31 | Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023) |
| "Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats." | 8.12 | Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022) |
| " The aim of this study is to explore the renal fibrosis and investigate the effect of losartan on renal fibrosis after the obstruction' relief using an improved mouse model of relief for unilateral ureteral obstruction (RUUO)." | 7.91 | Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. ( Jiang, C; Luo, J; Shi, GP; Song, J; Xia, Y; Yan, X; Zhang, M; Zhu, W, 2019) |
| "To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-β(1) (TGF-β(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis." | 7.77 | [Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction]. ( Du, H; Fu, JZ; Huang, YY; Xu, AP; Zhou, SS, 2011) |
| "To evaluate the effect of angiotensin receptor blocker (losartan) on renal function during and after relief of partial unilateral ureteral obstruction (PUO)." | 7.76 | Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). ( Abol-Enein, H; Abou-Bieh, E; Barakat, N; Mosbah, A; Shokeir, AA; Soliman, SA; Wafa, EW, 2010) |
| "To investigate the effects of angiotensin-converting enzyme inhibitor (cilazapril) and angiotensin II type I receptor antagonist (losartan) on tubular and interstitial cell apoptosis and caspase-3 activity in rats with obstructive nephropathy after unilateral ureteral obstruction." | 7.74 | Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats. ( Cuzić, S; Knotek, M; Radović, N, 2008) |
| "Unilateral ureteral obstruction (UUO) could induce increased renal angiotensin II (ANG II), which enhances apoptosis of renal tubular cells and renal tissue loss." | 7.73 | Apoptosis of circulating lymphocyte in rats with unilateral ureteral obstruction: role of angiotensin II. ( Eiam-Ong, S; Sueblinvong, T; Udom, J, 2005) |
| " Following the onset of ureteral obstruction, angiotensin II production is rapidly stimulated." | 7.70 | H+-ATPase activity on unilateral ureteral obstruction: interaction of endogenous nitric oxide and angiotensin II. ( Manucha, WA; Valles, PG, 2000) |
| "Renal angiotensin II (ANG II) is increased as a result of unilateral ureteral obstruction (UUO), and angiotensin AT(2) receptors predominate over AT(1) receptors in the early postnatal period." | 7.70 | Renal cellular response to ureteral obstruction: role of maturation and angiotensin II. ( Chevalier, RL; Thornhill, BA; Wolstenholme, JT, 1999) |
| "Renal fibrosis is the result of a complex combination of a variety of lesions." | 5.72 | Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022) |
| "Losartan treatment partially attenuated these responses." | 5.40 | Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014) |
| "In patients with anuria and oliguria, losartan treatment contributes to renal function recoverability after relief of calcular obstruction of the solitary kidney." | 5.34 | Effect of losartan on the recoverability of renal function in anuric and oliguric patients with a solitary obstructed kidney: a double-blind randomized placebo-controlled trial. ( Elkappany, S; Elkarta, A; Hashem, A; Osman, Y; Sheashaa, H; Shokeir, AA, 2020) |
| "Tubulointerstitial fibrosis is considered to be common endpoint result of many forms of chronic renal diseases." | 5.31 | Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. ( Dai, C; Liu, Y; Yang, J, 2002) |
| " Unilateral ureteral obstruction (UUO) renal fibrosis model was established in mice by ligating the left ureter, and then randomly received losartan at a low dose (1 mg/kg) or a regular dose (3 mg/kg) for 2 weeks." | 4.31 | Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells. ( Gu, W; Huang, Z; Li, P; Li, TS; Liu, G; Nie, H; Peng, YH; Xiao, J, 2023) |
| "Via interaction with AT1R and MasRs, daidzein improved glomerulosclerosis, oxidative stress, and inflammation in UUO-OVX rats." | 4.12 | Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions. ( Askaripour, M; Jafari, E; Najafipour, H; Rajabi, S; Saberi, S, 2022) |
| " Similar to losartan, Dojuksan ameliorated kidney inflammation and fibrosis in UUO mice." | 4.02 | Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk. ( Dorotea, D; Ha, H; Jiang, S; Kim, DS; Oh, DS; Son, E, 2021) |
| " The aim of this study is to explore the renal fibrosis and investigate the effect of losartan on renal fibrosis after the obstruction' relief using an improved mouse model of relief for unilateral ureteral obstruction (RUUO)." | 3.91 | Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs. ( Jiang, C; Luo, J; Shi, GP; Song, J; Xia, Y; Yan, X; Zhang, M; Zhu, W, 2019) |
| "100 healthy Sprague-Dawley rats were randomly divided into 5 groups: Unilateral ureteral obstruction (UUO) group, sham-operation (SOR) group, Radix Notoginseng (RN) group, compound Radix Notoginseng (CRN) group and Losartan (ARB) group." | 3.78 | [Investigate the effects of compound radix notoginseng on renal interstitial fibrosis and kidney-targeting treatment]. ( Fan, JM; Feng, SG; Liu, HC; Xie, XS; Yuan, W; Zhang, CL; Zhang, ZY; Zuo, C, 2012) |
| "To investigate the effect of losartan on the expression of monocyte chemoattractant protein-1 (MCP1) and transforming growth factor-β(1) (TGF-β(1)) in the kidney of rats with unilateral urethral obstruction (UUO) and evaluate protective effect of losartan against reanal interstitial fibrosis." | 3.77 | [Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction]. ( Du, H; Fu, JZ; Huang, YY; Xu, AP; Zhou, SS, 2011) |
| "To evaluate the effect of angiotensin receptor blocker (losartan) on renal function during and after relief of partial unilateral ureteral obstruction (PUO)." | 3.76 | Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan). ( Abol-Enein, H; Abou-Bieh, E; Barakat, N; Mosbah, A; Shokeir, AA; Soliman, SA; Wafa, EW, 2010) |
| "To investigate the effects of angiotensin-converting enzyme inhibitor (cilazapril) and angiotensin II type I receptor antagonist (losartan) on tubular and interstitial cell apoptosis and caspase-3 activity in rats with obstructive nephropathy after unilateral ureteral obstruction." | 3.74 | Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats. ( Cuzić, S; Knotek, M; Radović, N, 2008) |
| "Unilateral ureteral obstruction (UUO) could induce increased renal angiotensin II (ANG II), which enhances apoptosis of renal tubular cells and renal tissue loss." | 3.73 | Apoptosis of circulating lymphocyte in rats with unilateral ureteral obstruction: role of angiotensin II. ( Eiam-Ong, S; Sueblinvong, T; Udom, J, 2005) |
| "Intrarenal concentration of angiotensin II increases after the onset of ureteral obstruction in the obstructed kidney." | 3.73 | Effect of losartan pretreatment on kidney lipid content after unilateral obstruction in rats. ( Alvarez, S; Carrizo, L; Manucha, W; Oliveros, L; Valles, P, 2005) |
| "Rats underwent unilateral ureteral obstruction and were given either drinking water or losartan for 21 days." | 3.73 | Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction. ( Chen, J; El Chaar, M; Felsen, D; Kellner, D; Poppas, D; Richardson, I; Seshan, SV; Vaughan, ED, 2006) |
| " We examined the effect of an angiotensin II receptor inhibitor (AT(1)) losartan, independent from its effects on blood pressure, on nitric oxide synthase (NOS) isoforms and cyclooxygenase-2 (COX-2) expression and the significance of this interaction on interstitial fibrosis in UUO." | 3.72 | Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction. ( Carrizo, L; Manucha, W; Oliveros, L; Seltzer, A; Vallés, P, 2004) |
| "Unilateral ureteral obstruction in pigs is associated with an enhanced, de novo generation of angiotensin II from the ipsilateral kidney." | 3.71 | Losartan attenuates renal vasoconstriction in response to acute unilateral ureteral occlusion in pigs. ( Djurhuus, JC; Frøkiaer, J; Hvistendahl, JJ; Pedersen, EB; Pedersen, TS, 2002) |
| "Renal angiotensin II (ANG II) is increased as a result of unilateral ureteral obstruction (UUO), and angiotensin AT(2) receptors predominate over AT(1) receptors in the early postnatal period." | 3.70 | Renal cellular response to ureteral obstruction: role of maturation and angiotensin II. ( Chevalier, RL; Thornhill, BA; Wolstenholme, JT, 1999) |
| " Following the onset of ureteral obstruction, angiotensin II production is rapidly stimulated." | 3.70 | H+-ATPase activity on unilateral ureteral obstruction: interaction of endogenous nitric oxide and angiotensin II. ( Manucha, WA; Valles, PG, 2000) |
| "Adult male Sprague-Dawley rats were subjected to partial unilateral ureteral obstruction (UUO) and divided into two groups, that is, those treated with (group L, N = 21) and those without (group C, N = 21) an angiotensin type 1 (AT1) receptor antagonist (losartan)." | 3.70 | Salutary role for angiotensin in partial urinary tract obstruction. ( Fogo, AB; Fujinaka, H; Ichikawa, I; Inagami, T; Matsusaka, T; Miyazaki, Y; Yoshida, H, 2000) |
| "The effect of 24-hour unilateral ureteral obstruction (UUO) on the expression and regulation of the renin-angiotensin system (RAS) in rats and of pretreatment with lisinopril (5 mg/kg/day) or the AT1-R inhibitor, losartan, (10 mg/kg/day) on renal hemodynamics was evaluated." | 3.68 | Regulation of renin-angiotensin system in unilateral ureteral obstruction. ( Luo, C; Martinez-Maldonado, M; Pimentel, JL; Wang, S; Wilcox, JN, 1993) |
| "Renal fibrosis is the result of a complex combination of a variety of lesions." | 1.72 | Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad. ( Ma, Y; Yu, R; Zhou, X; Zou, J, 2022) |
| "Losartan treatment partially attenuated these responses." | 1.40 | Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy. ( He, P; Li, D; Zhang, B, 2014) |
| "AKF-PD was used to treat renal fibrosis in unilateral ureteral obstruction (UUO) obstructive nephropathy in rats." | 1.39 | Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. ( Cheng, GJ; Hu, GY; Huang, L; Mei, WJ; Peng, ZZ; Qin, J; Tao, LJ; Xie, YY; Yuan, QJ; Yuan, XN, 2013) |
| "Losartan treatment reduced the fibrosis in the CC UUO kidneys." | 1.38 | Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model. ( Brazin, JA; Chen, J; Estephan, R; Felsen, D; Kameue, T; Maack, T; Mora, R; O'Connor, N; Poppas, DP; Reid, AC; Seshan, SV; Silver, RB; Veerappan, A, 2012) |
| "Late losartan treatment had no effect on any of the parameters in either kidney, and PD-123319 had no effect on either kidney." | 1.34 | Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat. ( Burt, LE; Chevalier, RL; Coleman, CM; Forbes, MS; Minor, JJ; Thornhill, BA, 2007) |
| "Renal fibrosis was evaluated through TGFbeta expression and superoxide dismutase (SOD) activity, hydroxyl radicals, O2- and total antioxidant activity were measured by spectrophotometric assay." | 1.33 | Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy. ( Carrizo, L; Manucha, W; Molina, H; Ruete, C; Vallés, P, 2005) |
| "Tubulointerstitial fibrosis is considered to be common endpoint result of many forms of chronic renal diseases." | 1.31 | Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice. ( Dai, C; Liu, Y; Yang, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (18.92) | 18.2507 |
| 2000's | 12 (32.43) | 29.6817 |
| 2010's | 13 (35.14) | 24.3611 |
| 2020's | 5 (13.51) | 2.80 |
| Authors | Studies |
|---|---|
| Askaripour, M | 1 |
| Najafipour, H | 1 |
| Saberi, S | 1 |
| Jafari, E | 1 |
| Rajabi, S | 1 |
| Zou, J | 1 |
| Zhou, X | 1 |
| Ma, Y | 1 |
| Yu, R | 1 |
| Huang, Z | 1 |
| Nie, H | 1 |
| Liu, G | 1 |
| Li, P | 1 |
| Peng, YH | 1 |
| Xiao, J | 1 |
| Gu, W | 1 |
| Li, TS | 1 |
| Song, J | 1 |
| Xia, Y | 1 |
| Yan, X | 1 |
| Luo, J | 1 |
| Jiang, C | 1 |
| Zhang, M | 1 |
| Shi, GP | 1 |
| Zhu, W | 1 |
| Elkappany, S | 1 |
| Hashem, A | 1 |
| Elkarta, A | 1 |
| Sheashaa, H | 1 |
| Osman, Y | 1 |
| Shokeir, AA | 2 |
| Jiang, S | 1 |
| Oh, DS | 1 |
| Dorotea, D | 1 |
| Son, E | 1 |
| Kim, DS | 1 |
| Ha, H | 1 |
| Hosseinian, S | 2 |
| Rad, AK | 1 |
| Bideskan, AE | 1 |
| Soukhtanloo, M | 2 |
| Sadeghnia, H | 1 |
| Shafei, MN | 2 |
| Motejadded, F | 1 |
| Mohebbati, R | 1 |
| Shahraki, S | 2 |
| Beheshti, F | 1 |
| Ebrahimzadeh Bideskan, A | 1 |
| Sadeghnia, HR | 1 |
| Samadi Noshahr, Z | 1 |
| Khajavi Rad, A | 1 |
| Qin, J | 1 |
| Xie, YY | 1 |
| Huang, L | 1 |
| Yuan, QJ | 1 |
| Mei, WJ | 1 |
| Yuan, XN | 1 |
| Hu, GY | 1 |
| Cheng, GJ | 1 |
| Tao, LJ | 1 |
| Peng, ZZ | 1 |
| He, P | 1 |
| Li, D | 1 |
| Zhang, B | 1 |
| de Jong, MA | 1 |
| Mirkovic, K | 1 |
| Mencke, R | 1 |
| Hoenderop, JG | 1 |
| Bindels, RJ | 1 |
| Vervloet, MG | 1 |
| Hillebrands, JL | 1 |
| van den Born, J | 1 |
| Navis, G | 1 |
| de Borst, MH | 1 |
| Fang, J | 1 |
| Wang, W | 1 |
| Sun, S | 1 |
| Wang, Y | 1 |
| Li, Q | 1 |
| Lu, X | 1 |
| Qiu, M | 1 |
| Zhang, Y | 1 |
| Radović, N | 1 |
| Cuzić, S | 1 |
| Knotek, M | 1 |
| Soliman, SA | 1 |
| Mosbah, A | 1 |
| Abol-Enein, H | 1 |
| Barakat, N | 1 |
| Abou-Bieh, E | 1 |
| Wafa, EW | 1 |
| Huang, YY | 1 |
| Xu, AP | 1 |
| Zhou, SS | 1 |
| Fu, JZ | 1 |
| Du, H | 1 |
| Veerappan, A | 1 |
| Reid, AC | 1 |
| O'Connor, N | 1 |
| Mora, R | 1 |
| Brazin, JA | 1 |
| Estephan, R | 1 |
| Kameue, T | 1 |
| Chen, J | 2 |
| Felsen, D | 2 |
| Seshan, SV | 2 |
| Poppas, DP | 1 |
| Maack, T | 1 |
| Silver, RB | 1 |
| Kusunoki, H | 1 |
| Taniyama, Y | 1 |
| Azuma, J | 1 |
| Iekushi, K | 1 |
| Sanada, F | 1 |
| Otsu, R | 1 |
| Iwabayashi, M | 1 |
| Okayama, K | 1 |
| Rakugi, H | 1 |
| Morishita, R | 1 |
| Xie, XS | 1 |
| Zuo, C | 1 |
| Zhang, ZY | 1 |
| Liu, HC | 1 |
| Feng, SG | 1 |
| Zhang, CL | 1 |
| Yuan, W | 1 |
| Fan, JM | 1 |
| Bocanegra, V | 1 |
| Rinaldi Tosi, M | 1 |
| Gil Lorenzo, A | 1 |
| Cacciamani, V | 1 |
| Manucha, W | 4 |
| Fornés, M | 1 |
| Vallés, PG | 2 |
| Hvistendahl, JJ | 1 |
| Pedersen, TS | 1 |
| Djurhuus, JC | 1 |
| Pedersen, EB | 1 |
| Frøkiaer, J | 1 |
| Yang, J | 1 |
| Dai, C | 1 |
| Liu, Y | 1 |
| Oliveros, L | 2 |
| Carrizo, L | 3 |
| Seltzer, A | 1 |
| Vallés, P | 3 |
| Eiam-Ong, S | 2 |
| Udom, J | 1 |
| Sueblinvong, T | 1 |
| Alvarez, S | 1 |
| Ruete, C | 1 |
| Molina, H | 1 |
| Kellner, D | 1 |
| Richardson, I | 1 |
| El Chaar, M | 1 |
| Vaughan, ED | 1 |
| Poppas, D | 1 |
| Coleman, CM | 1 |
| Minor, JJ | 1 |
| Burt, LE | 1 |
| Thornhill, BA | 4 |
| Forbes, MS | 1 |
| Chevalier, RL | 5 |
| Chung, KH | 1 |
| Gomez, RA | 1 |
| Pimentel, JL | 3 |
| Wang, S | 3 |
| Martinez-Maldonado, M | 3 |
| Wilcox, JN | 1 |
| Luo, C | 1 |
| el-Dahr, SS | 1 |
| Gee, J | 1 |
| Dipp, S | 1 |
| Hanss, BG | 1 |
| Vari, RC | 1 |
| Chao, J | 1 |
| Sundell, CL | 1 |
| Kopp, JB | 1 |
| Montero, A | 1 |
| McDowell, KA | 1 |
| Norling, LL | 1 |
| Wolstenholme, JT | 1 |
| Yoo, KH | 1 |
| Manucha, WA | 1 |
| Fujinaka, H | 1 |
| Miyazaki, Y | 1 |
| Matsusaka, T | 1 |
| Yoshida, H | 1 |
| Fogo, AB | 1 |
| Inagami, T | 1 |
| Ichikawa, I | 1 |
1 trial available for losartan and Ureteral Obstruction
| Article | Year |
|---|---|
Effect of losartan on the recoverability of renal function in anuric and oliguric patients with a solitary obstructed kidney: a double-blind randomized placebo-controlled trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Anuria; Creatinine; Double-Blind Method; Femal | 2020 |
36 other studies available for losartan and Ureteral Obstruction
| Article | Year |
|---|---|
Daidzein Mitigates Oxidative Stress and Inflammation in the Injured Kidney of Ovariectomized Rats: AT1 and Mas Receptor Functions.
Topics: Aged; Animals; Antioxidants; Female; Fibrosis; Humans; Inflammation; Isoflavones; Kidney; Losartan; | 2022 |
Losartan ameliorates renal interstitial fibrosis through metabolic pathway and Smurfs-TGF-β/Smad.
Topics: Animals; Fibrosis; Kidney; Kidney Diseases; Losartan; Male; Metabolic Networks and Pathways; Mice; M | 2022 |
Losartan alleviates renal fibrosis by inhibiting the biomechanical stress-induced epithelial-mesenchymal transition of renal epithelial cells.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Epithelial Cell | 2023 |
Losartan accelerates the repair process of renal fibrosis in UUO mouse after the surgical recanalization by upregulating the expression of Tregs.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Fibrosis; Kidney; Losartan; Male; Mice; Mice, Inb | 2019 |
Dojuksan ameliorates tubulointerstitial fibrosis through irisin-mediated muscle-kidney crosstalk.
Topics: Animals; Cell Line; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney Diseases; | 2021 |
Thymoquinone ameliorates renal damage in unilateral ureteral obstruction in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzoquinones; Biomarkers; Captopr | 2017 |
Nigella sativa extract is a potent therapeutic agent for renal inflammation, apoptosis, and oxidative stress in a rat model of unilateral ureteral obstruction.
Topics: Angiotensin II; Animals; Apoptosis; Captopril; Chemokine CCL2; Creatinine; Fibrosis; Inflammation; K | 2018 |
Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis.
Topics: Angiotensin II; Animals; Antioxidants; Cell Line; Class Ia Phosphatidylinositol 3-Kinase; Collagen T | 2013 |
Losartan attenuates renal interstitial fibrosis and tubular cell apoptosis in a rat model of obstructive nephropathy.
Topics: Actins; Animals; Apoptosis; bcl-2-Associated X Protein; Collagen Type I; Dimethyl Sulfoxide; Disease | 2014 |
Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblast Gr | 2017 |
Metabolomics study of renal fibrosis and intervention effects of total aglycone extracts of Scutellaria baicalensis in unilateral ureteral obstruction rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Blood Urea Nitrogen; Creatinine; Discr | 2016 |
Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
Recoverability of renal function after relief of chronic partial unilateral ureteral obstruction: study of the effect of angiotensin receptor blocker (losartan).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chronic Disease; Dogs; Kidney Diseases; Losartan; | 2010 |
[Effect of losartan on renal expression of monocyte chemoattractant protein-1 and transforming growth factor-β(1) in rats after unilateral ureteral obstruction].
Topics: Animals; Chemokine CCL2; Fibrosis; Kidney; Losartan; Male; Rats; Rats, Sprague-Dawley; Transforming | 2011 |
Mast cells are required for the development of renal fibrosis in the rodent unilateral ureteral obstruction model.
Topics: Angiotensin II; Animals; Cell Degranulation; Fibrosis; Humans; In Vitro Techniques; Kidney; Kidney D | 2012 |
Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antibodies; Benzimidazoles; Benzoates; C | 2012 |
[Investigate the effects of compound radix notoginseng on renal interstitial fibrosis and kidney-targeting treatment].
Topics: Actins; Animals; Collagen Type I; Drugs, Chinese Herbal; Fibronectins; Fibrosis; Kidney; Losartan; M | 2012 |
Angiotensin AT(1) receptor inhibition-induced apoptosis by RhoA GTPase activation and pERK1/2 signaling pathways in neonatal obstructive nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Apoptosis; Blotting, Western; Di | 2012 |
Losartan attenuates renal vasoconstriction in response to acute unilateral ureteral occlusion in pigs.
Topics: Acute Disease; Aldosterone; Angiotensin II; Animals; Glomerular Filtration Rate; Kidney; Losartan; P | 2002 |
Hepatocyte growth factor gene therapy and angiotensin II blockade synergistically attenuate renal interstitial fibrosis in mice.
Topics: Actins; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cells, Cultured; Drug Synergism; | 2002 |
Losartan modulation on NOS isoforms and COX-2 expression in early renal fibrogenesis in unilateral obstruction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Base Sequence; Cyclooxygenase 2; Female; Fibrosis; | 2004 |
Apoptosis of circulating lymphocyte in rats with unilateral ureteral obstruction: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
Effect of losartan pretreatment on kidney lipid content after unilateral obstruction in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cholesterol; Fatty Acids; Female; | 2005 |
Angiotensin II type I antagonist on oxidative stress and heat shock protein 70 (HSP 70) expression in obstructive nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Female; Fibrosis; Gene Expression | 2005 |
Angiotensin receptor blockade decreases fibrosis and fibroblast expression in a rat model of unilateral ureteral obstruction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Fibroblasts; Fibrosis; Los | 2006 |
Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin | 2007 |
Regulation of renal growth factors and clusterin by AT1 receptors during neonatal ureteral obstruction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Biphenyl Compounds; Blo | 1995 |
Regulation of the renal angiotensin II receptor gene in acute unilateral ureteral obstruction.
Topics: Acute Disease; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Down-R | 1994 |
Regulation of renin-angiotensin system in unilateral ureteral obstruction.
Topics: Animals; Biphenyl Compounds; Blotting, Northern; Dipeptides; Diuresis; Eicosanoids; Electrolytes; He | 1993 |
Upregulation of renin-angiotensin system and downregulation of kallikrein in obstructive nephropathy.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Gene Expression; Imidazoles; Kallikrein | 1993 |
Role of angiotensin II in the expression and regulation of transforming growth factor-beta in obstructive nephropathy.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Gene Expression; Imidazoles; Immunohistochemistry; Kidn | 1995 |
Unilateral ureteral obstruction increases glomerular soluble guanylyl cyclase activity.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compoun | 1995 |
Renal cellular response to ureteral obstruction: role of maturation and angiotensin II.
Topics: Age Factors; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Imidazoles | 1999 |
Angiotensin stimulates TGF-beta1 and clusterin in the hydronephrotic neonatal rat kidney.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Clusterin; Glycoproteins; Imidazoles; Kidney; Losa | 2000 |
H+-ATPase activity on unilateral ureteral obstruction: interaction of endogenous nitric oxide and angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Enzyme Activatio | 2000 |
Salutary role for angiotensin in partial urinary tract obstruction.
Topics: Angiotensin II; Animals; Kidney; Losartan; Male; Muscle Contraction; Muscle, Smooth; Pelvis; Perista | 2000 |